Lack of association between -174G>C and -634C>G polymorphisms in interleukin-6 promoter region and lung cancer risk: a meta-analysis.

Evidence suggested that the -174G>C and -634C>G polymorphisms in interleukin-6 (IL6) promoter region may modulate risk of lung cancer; however, the conclusion was still inconclusive. Therefore, we performed this meta-analysis to determine the association between IL6 -174G>C and -634C>G polymorphisms and lung cancer risk. The association strength was measured by odds ratios (ORs) and 95% confidence intervals (CI). Egger's test and Begg's test were performed to detect potential publication bias. By searching PubMed, EMBASE and China National Knowledge Infrastructure, we included 16 eligible studies in this meta-analysis, involving 6,202 lung cancer cases and 7,067 controls. Five studies about -174G>C polymorphism and 11 studies about -634C>G polymorphism were analyzed. By pooling eligible studies, we found no significant association of -174G>C with lung cancer risk (C vs. G: OR = 1.029; 95% CI, 0.957-1.106; heterogeneity, P = 0.478) and no statistic association of -634C > G with lung cancer susceptibility (G vs. C: OR = 1.050; 95% CI, 0.893-1.235; Heterogeneity, P < 0.001). No significant publication bias was observed. In conclusion, we found that -634C>G and -174G>C polymorphisms in IL6 promoter region were not associated with lung cancer risk.

Effects of interleukin-37 on cardiac function after myocardial infarction in mice.

BACKGROUND: Interleukin-37 (IL-37) is a new discovered member of the interleukin family and plays anti-inflammatory effect in some inflammatory disease. A recent study found that IL-37 elevated significantly in peripheral blood of patients with acute myocardial infarction. We aimed to explore the effect IL-37 on cardiac function after mice myocardial infarction (MI) and its mechanism. METHODS: Acute MI mouse model was established and divided into three groups: sham group, MI group and IL-37 treatment group. MPO expression was detected by immunohistochemistry; NF-κB signaling pathway was tested by Western blot; and cardiac function was measured by echocardiography. RESULTS: Compared with MI mice, IL-37 treatment showed an obvious decrease of MPO expression, suppression of p-p65 expression, and improved cardiac function by decreasing left ventricular shortening fraction (LVFS). CONCLUSION: IL-37 may improve MI mice cardiac function via inhibition of inflammatory NF-κB signaling pathway.